Literature DB >> 17882651

TrkC: a new predictive marker in breast cancer?

María Jesús Blasco-Gutiérrez1, Isabel Julia San José-Crespo, Enrique Zozaya-Alvarez, Rafael Ramos-Sánchez, Natividad García-Atarés.   

Abstract

Available data involve neurotrophins and their receptors in carcinomas. Quantitative evaluation of these molecules in these tumors might be useful as prognostic marker and eventual treatments. Our study on 40 mammary tumors tries to correlate expression of these molecules and prognosis. Immunohistochemistry for NGF, BDNF, NT3, TrkA, TrkB, TrkC, and p75 was used. Patient's age, histopathology, Bloom-Richardson grading, estrogen and progesterone receptors, Ki-67 index, HER-2, p53 were evaluated. Statistics found inverse relationship between grading and TrkC expression. We found significantly higher TrkC expression in Grade I than in Grade III tumors. Rise in TrkC expression could indicate good prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882651     DOI: 10.1080/07357900701206349

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  10 in total

1.  TrkC expression predicts favorable clinical outcome in invasive ductal carcinoma of breast independent of NT-3 expression.

Authors:  Wei Zhang; Zhi-Chun Lin; Tong-Xian Zhang; Shan Liu; Xia Liu; Jun-Jun Liu; Yun Niu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

2.  TrkC-Targeted Kinase Inhibitors And PROTACs.

Authors:  Bosheng Zhao; Kevin Burgess
Journal:  Mol Pharm       Date:  2019-09-12       Impact factor: 4.939

3.  Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis.

Authors:  Jimena Bouzas-Rodriguez; Jorge Ruben Cabrera; Céline Delloye-Bourgeois; Gabriel Ichim; Jean-Guy Delcros; Marie-Anne Raquin; Raphaël Rousseau; Valérie Combaret; Jean Bénard; Servane Tauszig-Delamasure; Patrick Mehlen
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

4.  An agent for optical imaging of TrkC-expressing, breast cancer.

Authors:  Anyanee Kamkaew; Feng Li; Zheng Li; Kevin Burgess
Journal:  Medchemcomm       Date:  2017-09-14       Impact factor: 3.597

5.  Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer.

Authors:  Neill Patani; Wen G Jiang; Kefah Mokbel
Journal:  Cancer Cell Int       Date:  2011-07-18       Impact factor: 5.722

6.  Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy.

Authors:  Parveen Kumar; Chandana C Barua; Kunjbihari Sulakhiya; Rajeev Kumar Sharma
Journal:  Front Pharmacol       Date:  2017-04-04       Impact factor: 5.810

7.  Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.

Authors:  Li Ge; Ning Li; Mei Liu; Ning-Zhi Xu; Ming-Rong Wang; Ling-Ying Wu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

8.  Developmental and lactational exposure to dieldrin alters mammary tumorigenesis in Her2/neu transgenic mice.

Authors:  Heather L Cameron; Warren G Foster
Journal:  PLoS One       Date:  2009-01-28       Impact factor: 3.240

9.  BDNF is associated with SFRP1 expression in luminal and basal-like breast cancer cell lines and primary breast cancer tissues: a novel role in tumor suppression?

Authors:  Laura Huth; Michael Rose; Veronika Kloubert; Wiebke Winkens; Martin Schlensog; Arndt Hartmann; Ruth Knüchel; Edgar Dahl
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

10.  Targeted PDT agent eradicates TrkC expressing tumors via photodynamic therapy (PDT).

Authors:  Chin Siang Kue; Anyanee Kamkaew; Hong Boon Lee; Lip Yong Chung; Lik Voon Kiew; Kevin Burgess
Journal:  Mol Pharm       Date:  2014-12-09       Impact factor: 4.939

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.